Biodesix, Inc.
BDSX
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malā¦ read more
Healthcare
Diagnostics & Research
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$22.03
Price+3.92%
$0.83
1Y
Price
Market Cap
$179.330m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-17.2%
EBITDA Margin-30.5%
Net Profit Margin-40.3%
Free Cash Flow Margin-17.2%
EBITDA Margin-30.5%
Net Profit Margin-40.3%
Free Cash Flow MarginRevenue
$96.096m
+8.6%
1y CAGR+26.0%
3y CAGR+26.6%
5y CAGREarnings
-$31.957m
+9.4%
1y CAGR+15.0%
3y CAGR+16.3%
5y CAGREPS
-$4.02
+13.9%
1y CAGR+30.4%
3y CAGR+37.6%
5y CAGRBook Value
$9.132m
$94.637m
Assets$85.505m
Liabilities$71.610m
DebtDebt to Assets
75.7%
-3.9x
Debt to EBITDAFree Cash Flow
-$25.248m
-6.6%
1y CAGR+11.6%
3y CAGR+10.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company